NEWS
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China. Conducted by GenFleet Therapeutics, this trial is part of a collaboration established in 2023. The trial aims to evaluate GFH375/VS-7375's safety and efficacy in patients with advanced KRAS G12D mutant solid tumors. Initial preclinical data showed strong anti-tumor activity and potential for brain metastases treatment. Verastem plans to initiate development studies outside China after analyzing the Phase 1 dose escalation data.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1170Followers
73Following
8178Visitors
Follow